Tag Archives: VC

Hot Life Science Investor Mandate 2: Australian VC Looking Overseas for Life Science Opportunities

3 Jul

A venture capital firm headquartered in Melbourne, Australia is looking to make makes equity investments from $3M-5M. The firm anticipates about 6 new investments this year and looks to invest invests globally.

The firm will invest in companies across the life science space, including therapeutics, diagnostics and medical technology. The group does not invest in service providers. The firm considers all subsectors and indications, including orphan indications. The group will consider technology either in or prepared for human clinical trials and is open to all classes of devices. The firm seeks investments in novel technology and is not looking to gain share of an existing market.

The firm is open to co-investments and considers public or private companies. The group will only consider companies with granted patents or a clear patent strategy. Companies of interest must have a remote connection with Australia or the Pacific Region. This may include a facility or a partner located in the region.

If you are interested in more information about this investor and other investors tracked by LSN, please emailĀ mandates@lifesciencenation.com

Tags: , , , , , ,

Hot Life Science Investor Mandate 3: VC is Interested in Single Use Devices, Several Indications

18 Dec

A venture capital company based in the Western US has raised 2 funds to date, and is currently investing out of its 2nd $15 million dollar fund. The firm makes primarily equity investments ranging from $50,000 to $5 million over the lifetime of the investment. The firm is looking for companies located within the United States and plans to make approximately 2 new investments over the next 6-9 months.

The VC is looking for seed and venture stage medical and diagnostic device companies. In these areas the firm is most interested in single use devices capable of delivering a therapy, and in indications such as cancer, cardiovascular and neurological diseases, orthopedic problems, respiratory conditions, and gastrointestinal disorders. While this is the firms primary focus, they remain open minded to other types of devices and indications as well.

The VC looks for professionalism in a firms management teams and is willing to work with firms that do not yet have a complete management team in place.

Tags: ,

Hot Life Science Investor Mandate 3: VC Incubator Seeks Wide Range of Early Stage Opportunities

12 Dec

A life-sciences focused venture capital incubator / accelerator based in the Western US is looking to provide capital in the form of equity and convertible notes to seed and venture stage companies in the life science space. The firm can provide capital in the range of a few hundred thousand to $2 million or more by leveraging its groups of angel syndicates. The firm invests in companies across the United States, Europe and Australia with a preference for California based companies. The firm looks to be involved in 3 new companies per year. The VC is currently looking for companies in areas of Medical Technology / Devices, Therapeutics and Companion Diagnostics. In the Medical Device space the firm is open in terms of sector and indication and will consider firms that are in the development phase as well as those that have entered clinical trials. In the therapeutics space the firm is generally open as well however the firm is highly interested in areas of cell and gene therapy and oncology. For therapeutics the firm tends to get involved at the preclinical stage or during phase I of clinical trials. The firm is looking for confident and experienced management teams. Given the early stage investment style that the firm has, they often work with management teams that are incomplete and have primarily academic backgrounds. Part of the value that the firm looks to add is helping firms fill in the gaps in their current management.

Tags: , ,

LSN Investor Database Feature: Non-VC Interest in Early Stage Medtech

4 Dec

By Max Klietmann, VP of Marketing, LSN

Recently, I wrote a feature detailing the increasing number of non-VC entities investing in early stage biotech companies. Due to the interest that article generated, weā€™ve decided to follow on with another LSN Investor Database Feature; this edition will focus on the early-stage investor interest in the medtech arena.

As mentioned in the previous feature, LSNā€™s investor research group maintains quarterly contact with over 5,000 active investors in the life science space, with a particular focus on those categories filling the void left by Venture Capital. This gives LSN unprecedented insight into what private investor trends look like today and going forward.

The chart below shows the results ofĀ an LSN Investor Database searchĀ mapping out all non-venture capital investors tracked by LSN with a declared interest ā€“ or mandate ā€“ in seed/venture stage medical technology companies with a prototype or early-stage clinical asset. The result is 561 investors globally. This should be very encouraging news to the executives of a space that has seen a great deal of turbulence in recent years in terms of fundraising trends.

Chart Issue 46Click to Enlarge

So whatā€™s the next step? If youā€™re an early-stage medtech looking to raise money, these investor categories should certainly be on your radar. Second, do your homework on how exactly these categories behave in terms of investment activity. LSNā€™s research team can help elucidate this information on an investor-by investor basis. Finally, the space is in flux, so stay tuned as LSN continues to offer insights on the changing medical technology investor landscape.

Tags: , ,

Hot Life Science Investor Mandate 3: VC Looks to Companies in Pre-Clinical Trials

20 Nov

A venture capital firm based in the Central US manages 2 funds for a combined total of more than $250 million in assets under management. The firm generally invests between $2-$6 million of equity capital per round, and up to $10 million over the life of the investment. The firm plans to invest in 2-5 companies over the next 6-9 months, and will consider firms located throughout the United States. The VC looks to syndicate with other venture firms, and often acts as the lead investor.

Currently, this organization is looking for companies developing Medical Devices, Therapeutics, Diagnostics and Healthcare IT products. For medical devices and therapeutics, the firm is open to the full spectrum of subsector and indication, and will consider companies developing orphan indications. They are interested in seed and venture stage companies, generally looking to invest in companies with a lead asset in pre-clinical trials. Only in certain cases of reformulation and repurposing would the firm consider investment into a company with a product in clinical trials. They are also willing to consider companies targeting orphan indications. In the Healthcare IT space, the firm has stated interest in areas of clinical sequencing and diagnostic platforms but will also consider other companies that fall into the Healthcare IT space as well with the exception of tradition EMR companies.

As such an early stage investor, they invest almost exclusively in pre-revenue companies. The firm also looks for experienced management teams and generally takes a seat on the companyā€™s board.

Tags: , ,

Hot Life Science Investor Mandate 3: Opportunistic European VC Actively Seeking New Investments

6 Nov

A venture capital firm with several offices worldwide is based primarily in Europe, and co-manages an early-stage fund focused on academic spinouts and seed investments in Europe. The firm has approximately ā‚¬500M AUM, and is currently managing four active funds. The firm makes equity investments in life science and biomedical technology companies at all stages of development. However, the VC prefers late stage preclinical or early stage clinical for therapeutics and diagnostics and medical devices that are close to market approval. The typical investment per round is ā‚¬3M to ā‚¬7M. The firm looks for companies that are based in the US, Canada, and Europe. They are actively screening new investment opportunities.

This group is fairly opportunistic in the life sciences space, but generally targets therapeutics and diagnostics, medical devices, and biopharmaceuticals. In therapeutics, the firm focuses on drug development and has no specific preference in indication. In medical devices, they have a special focus on interventional devices in cardiology, gastroenterology and pulmonology that are close to or on the market approval. However, the firm is equally opportunistic in other subsectors and indications for medical devices, but all with a therapeutic focus.

The VC invests in companies at all stages of their development. For drug development, they invest from late preclinical to mid-stage clinical development. Sometimes they will consider companies with products on the market. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

Tags: , , ,

Hot Life Science Investor Mandate 1: VC Arm of Larger Fund Looks to Grow in 2013 ā€“ January 22, 2013

22 Jan

A fund located in North America with around $200 million in current AUM will grow to $400 million in assets by the end of 2013. The fund is the venture capital arm of a larger fund with AUM upward of $50 billion. Over the last 12 months, the group has allocated to more than 10 firms, making the VC number one in its region. The firm is currently looking for new opportunities in the life science space within the next 6-9 months. They typically allocate anywhere between $500,000 and $50 million per firm. The group is a lifecycle investor, which allows them to deploy capital throughout a firmā€™s entire financing lifecycle, and thus participate in every round of financing.

The firm is currently looking for companies in the information provider space, and is particularly interested in healthcare IT firms. The firm has a global investment mandate, but prefers North American targets for allocation.

The firm almost entirely invests in companies that are pre-revenue, but will consider companies that are not cash-flow-positive. The fund will consider firms with products on the market on a discretionary basis, but has no strict requirements in terms of their EBITDA or annual revenue.

Tags: , , , , , , , , ,

Newer Entries →